Vaxart reports positive 12-month safety data from Phase 2b sentinel cohort of oral COVID-19 vaccine

Vaxart, Inc.

No vaccine-related SAEs or sustained Grade 3+ AEs in either arm (201 oral pill, 199 mRNA).
Most common AEs for oral pill: malaise/fatigue (20.9%), headache (18.9%), anorexia (10.0%).
Sentinel cohort not powered for efficacy; 33 symptomatic COVID cases in oral arm vs 30 in mRNA arm.
Complete study data (~5,000 main cohort participants) anticipated in 2027.
Project NextGen/BARDA award valued at up to $344.8 million supports the trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.